The Hyundai Grand i10 NIOS BS6 petrol variant mileage figures have been revealed. The company had updated the petrol engine to achieve BS6 compliance earlier this year, and also added a new turbo-engine to the Grand i10 NIOS BS6.

Online Resource

Online Resource

If you hate GoPro's rectangular shape, your prayers have been answered! Sort of. We took the new Hero4 Session into rivers, lakes, and surf, off cliffs and platforms, through trees and go kart courses. Our full review will tell you everything you need to know.

Online Resource

Online Resource

Okamoto, Yohei, author

The Law Library of Congress is proud to present the report,  Powers of the Mexican Federal Police with Foreign Country Comparisons.

After discussing Mexico’s historical and current policing structure, this report then examines the structure of police forces in selected other countries. The main criteria for the inclusion of other countries was the functional and geographic divergence of law enforcement duties across various jurisdictional levels. The list of countries included is not intended to be exhaustive.

This report is one of many prepared by the Law Library of Congress. Visit the Comprehensive Index of Legal Reports page for a complete listing of reports and the Current Legal Topics page for our highlighted and newer reports. 

A comparison of stage at cancer diagnosis and cancer treatment rates between people with HIV (PWH) and the general US population is needed to identify any disparities by HIV status.

This study examines when nonexperiments might substitute for experiments that are done in real-world settings in order to learn what works to affect some socially valued outcome.

WordPress is super versatile. You know that. I know that. But sometimes this can be an overwhelming prospect. How on earth will you get your site up and running? What platform will you use? Zurb Foundation and Bootstrap are two …

Dewey Library - HX550.R48 B5213 2018

Rotch Library - HT185.P833 2019

Interview with William J. Calhoun, MD, author of Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma: The BASALT Randomized Controlled Trial

Interview with Maria C. Raven, MD, MPH, MSc, author of Comparison of Presenting Complaint vs Discharge Diagnosis for Identifying "Nonemergency" Emergency Department Visits

Interview with Matthew D. Barber, MD, MHS, author of Comparison of 2 Transvaginal Surgical Approaches and Perioperative Behavioral Therapy for Apical Vaginal Prolapse

Interview with Mohamed Abdel-Wahab, MD, author of Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement: The CHOICE Randomized Clinical Trial

Interview with Bradley C. Johnston, PhD, author of Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults: A Meta-analysis

Interview with Timothy E. McAlindon, MD,MPH, author of Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial

Cottingham, Alan, author

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.